Citigroup’s Tyra Biosciences TYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.99M Buy
62,279
+56,288
+940% +$1.86M ﹤0.01% 2938
2026
Q1
$229K Buy
5,991
+2,174
+57% +$70.4K ﹤0.01% 3946
2025
Q4
$100K Buy
3,817
+2,110
+124% +$38.8K ﹤0.01% 4323
2025
Q3
$23.9K Sell
1,707
-7,790
-82% -$88.8K ﹤0.01% 4767
2025
Q2
$90.9K Sell
9,497
-6,010
-39% -$57.1K ﹤0.01% 4452
2025
Q1
$144K Sell
15,507
-1,296
-8% -$16.8K ﹤0.01% 4387
2024
Q4
$234K Buy
16,803
+2,136
+15% +$38.8K ﹤0.01% 4326
2024
Q3
$345K Buy
14,667
+10,234
+231% +$215K ﹤0.01% 3977
2024
Q2
$70.9K Sell
4,433
-2,673
-38% -$46K ﹤0.01% 4393
2024
Q1
$117K Buy
7,106
+5,075
+250% +$83.2K ﹤0.01% 4229
2023
Q4
$28.1K Buy
2,031
+2,012
+10,589% +$26K ﹤0.01% 4847
2023
Q3
$262 Sell
19
-4,146
-100% -$61.5K ﹤0.01% 5287
2023
Q2
$70.9K Buy
+4,165
New +$60.4K ﹤0.01% 4423
2023
Q1
Sell
-89
Closed -$676 5867
2022
Q4
$676 Sell
89
-111
-56% -$785 ﹤0.01% 5465
2022
Q3
$2K Sell
200
-734
-79% -$6.71K ﹤0.01% 5540
2022
Q2
$7K Buy
934
+475
+103% +$3.78K ﹤0.01% 5514
2022
Q1
$5K Sell
459
-2,706
-85% -$32.1K ﹤0.01% 5841
2021
Q4
$45K Buy
3,165
+2,725
+619% +$54.1K ﹤0.01% 5122
2021
Q3
$8K Buy
+440
New +$8.41K ﹤0.01% 5526

Other funds holding TYRA

Citigroup's TYRA Position: Q2 2026 in Review

Citigroup increased its Tyra Biosciences (TYRA) stake by 940% in Q2 2026, buying an estimated $1.86M and bringing the position to 62,279 shares worth $1.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

Citigroup first reported a position in TYRA in Q3 2021 and has held it in 19 quarters since. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Citigroup held 62,279 shares of Tyra Biosciences worth $1.99M as of Q2 2026.
  • Citigroup bought 56,288 Tyra Biosciences shares in Q2 2026, an estimated $1.86M.
  • Tyra Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2938 holding.
  • Citigroup first reported a position in Tyra Biosciences in Q3 2021 and has held it in 19 quarters since.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.